about
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersEffects of communicating DNA-based disease risk estimates on risk-reducing behavioursProtein misfolding is the molecular mechanism underlying MCADD identified in newborn screeningWill nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases?Developing academic-practice partnerships to enhance the integration of genomics into public healthPersonal Genome Sequencing in Ostensibly Healthy Individuals and the PeopleSeq ConsortiumThe Human Genome Project, and recent advances in personalized genomicsThe future role of genetic screening to detect newborns at risk of childhood-onset hearing lossTranslational integrity and continuity: personalized biomedical data integrationUsing lifetime risk estimates in personal genomic profiles: estimation of uncertaintyEvidence for pleiotropic factors in genetics of the musculoskeletal systemACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingA research agenda for assessing the potential contribution of genomic medicine to tobacco control.The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicineMortality risk prediction by an insurance company and long-term follow-up of 62,000 menImpact of the environment on the skeleton: is it modulated by genetic factors?Being more realistic about the public health impact of genomic medicine.Genetic screening: A primer for primary care.Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls.HFE gene mutations increase the risk of coronary heart disease in women.The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop.Population screening for hereditary and familial cancer syndromes in Valka district of LatviaPopulation-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.DNA sequencing: bench to bedside and beyond.Measuring informed choice in population-based reproductive genetic screening: a systematic review.Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease.Genetic screening.Similarities in acquired factors related to postmenopausal osteoporosis and sarcopenia.Nutrigenetics: where next for the foods industry?Commentary: Children and predictive genomic testing: disease prevention, research protection, and our future.Genes and gene polymorphisms associated with periodontal disease.Unwarranted optimism in media portrayals of genetic research on addiction overshadows critical ethical and social concerns.Shaping science policy in the age of genomics.Implications of genomics for public health: the role of genetic epidemiology.Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study.BRCA1/2 population screening: embracing the benefits.Neonatal screening by DNA microarray: spots and chips.Screening for single gene genetic disease.
P2860
Q22330767-DDD8BC3E-A445-4141-A70B-6DDADC54A809Q24234616-68CEBF60-4525-4E03-A4DB-E673596A78FFQ24312099-E5B7A6CC-C78F-471F-9E99-289813344E3BQ24816319-7B4DB721-0156-4E2E-8B4F-CCD59252ABF6Q25257767-90E9BF92-33F7-46BF-966C-7ACDB979F04AQ26749580-1167D791-B24E-4AD2-94E6-BFEB361E6C99Q26861372-8E9476B9-C365-4D5F-A87E-5F1690C5B50BQ26863583-F17ADF3E-E0D1-4C37-81B6-FEE2D374C1A8Q28388444-6543E21F-0F54-4E15-A486-CBFD046F108BQ28392540-CAA505E8-945C-4322-B4DC-72BF5F17B0BBQ28603505-3BE2F209-4BFC-4688-840D-C0ED6CA0E0B6Q29616235-628509A3-37E1-4638-BED3-2AE06A190899Q30230101-AC6207A6-7730-48DB-9F62-126C01885982Q30585056-109BEBBF-DC40-40EE-81A7-F3EB3D96DC12Q33440570-FAD53F41-DE04-4689-ADC7-D0B7F074F72FQ33684679-F1E4E8BD-55BD-486C-97DF-439428D5A86CQ33725581-17FFC2E0-C7EC-464B-BD7D-57D545541618Q33815299-CE6E8215-B349-49AF-9430-E310C7E49B98Q34048798-12AABDFE-35BD-4BC7-A4E0-3138931C4021Q34098546-E638C389-1309-4A0E-8BF9-8E5855294BCCQ34113976-7F4FBE4D-E7E1-4D4D-AB41-927CE7E50BF4Q34297189-ADCBF37B-DD1B-42FE-9F3F-6135F04FBBE5Q34314370-A7E90251-325A-455D-9F39-A717797FE1E5Q34687071-CDA0E1B5-AC06-4256-83BF-04C99D86CB55Q34705206-9E731976-AE42-4011-85A3-5B6CFCE9CE51Q34879739-1042730F-1A27-460D-9CF2-D4180AE38DEFQ35116075-26A7ACBC-051B-4DB4-8F5A-AB123DA038B1Q35179023-C1317177-0BD1-4600-BC41-10B2B2810BF3Q35193941-A1E29C56-2D62-4674-9E13-F7AC7C48EF77Q35195120-74F1FD89-AECB-4737-B27C-757D5372CCFCQ35204071-DD3E6787-7460-47F9-A032-24C5D9A76B8AQ35423118-422FDACF-61B3-48E7-B3AD-D0115E093FB5Q35600726-6976B6E6-47AC-4787-B321-08FA1D95ED3CQ35671471-ABD8276D-4FC4-465A-A308-5A0A9EF9BF0CQ35767837-5DEF4867-6024-44F4-8F2E-99423BCA821BQ35875173-C63302EE-BA04-4B53-92BA-949CD739F4BCQ35914994-D370421B-33D8-418C-B47B-91909F47D34CQ35934264-462E89F0-53BB-4917-ADE8-B3175393A90CQ36045178-100853EE-6756-4788-A5E2-6DC065F5508AQ36054483-A27C56F4-C092-436A-985A-F7245946B392
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Population screening in the age of genomic medicine.
@en
type
label
Population screening in the age of genomic medicine.
@en
prefLabel
Population screening in the age of genomic medicine.
@en
P356
P1476
Population screening in the age of genomic medicine.
@en
P2093
Edward R B McCabe
Linda L McCabe
P356
10.1056/NEJMRA013182
P407
P577
2003-01-01T00:00:00Z